Literature DB >> 7159489

In vitro mass: activity distribution of lecithin--cholesterol acyltransferase among human plasma lipoproteins.

J Chung, D Abano, R Byrne, A M Scanu.   

Abstract

In order to compare the mass-activity distribution of lecithin-cholesterol acyltransferase (LCAT) among plasma lipoproteins separated by various ultracentrifugal or chromatographic procedures, we have quantified the enzyme by an electroimmunoassay technique using a specific antibody raised in the rabbit. This antibody, when added to whole serum, inhibited all of the enzyme activity present in it. The percent mass distribution of the enzyme among the lipoproteins isolated by rate-zonal ultracentrifugation (d 1.00-1.36 g/ml, SW 40 rotor, 37 000 rpm, 16 h) was as follows: very low density lipoproteins (VLDL), 0; low density lipoproteins (LDL), 6.2; HDL2, 6.5; HDL3, 12 and d greater than 1.21 g/ml fraction, 75. Measurement of LCAT activity of each lipoprotein fraction against mixed single bilayer lecithin-cholesterol vesicles (molar ratio, 4:1) containing apo A-I, indicated that VLDL, LDL and HDL2 were inactive or minimally active under the experimental conditions used, whereas HDL3 and the d greater than 1.21 g/ml fraction contained 17.5 and 79.9% of the total enzyme activity. Prolonged ultracentrifugation of the LCAT-containing lipoproteins resulted in the recovery of activity in the lipoprotein-free infranatant. In studies with lipoproteins linked to Sepharose 4B, LCAT was found to bind LDL, HDL2, and HDL3. It is concluded that LCAT is present in all the major lipoproteins except for VLDL. The activity appears to be dependent, at least in part, on the type of lipoproteins to which the enzyme is associated with.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7159489     DOI: 10.1016/0021-9150(82)90169-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  3 in total

1.  Role of the interfacial binding domain in the oxidative susceptibility of lecithin:cholesterol acyltransferase.

Authors:  Kewei Wang; Papasani V Subbaiah
Journal:  Biochem J       Date:  2002-08-01       Impact factor: 3.857

2.  Increased lysolecithin acyltransferase activity in the plasma of type II hyperlipoproteinemic patients.

Authors:  P V Subbaiah; J T Ogilvie
Journal:  Lipids       Date:  1984-02       Impact factor: 1.880

3.  Inhibition of cholesteryl ester transfer protein activity by monoclonal antibody. Effects on cholesteryl ester formation and neutral lipid mass transfer in human plasma.

Authors:  F T Yen; R J Deckelbaum; C J Mann; Y L Marcel; R W Milne; A R Tall
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.